Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00406211 | Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine | PHASE3 | COMPLETED | 398 | — | — | Jul 1, 2004 | Dec 1, 2004 | Sep 15, 2016 | 41 | Austria, Germany |
| Name | Type | Description |
|---|---|---|
| MMRV | BIOLOGICAL | - |
| MMR (Priorix®) | BIOLOGICAL | - |
| Varicella (Varilrix®) | BIOLOGICAL | - |
Inclusion Criteria: * Written informed consent from the parents/guardians of the child before participating in the long-term follow-up. * Subjects must have received their complete vaccination course according to the group allocation (i.e. subjects must have received either two doses of MMRV combin...